Antibody-drug conjugates (ADCs) and peptide drug conjugates (PDCs) are some of the more complex and powerful biopharmaceuticals available today. ADCs are challenging to develop and analyze for a number of reasons. Colin Barry, VP of Technology and Bioanalysis at Alliance Pharma, shares his perspective on advantages and disadvantages of using hybrid LBA/LC-MS as a technique to overcome the challenges we face developing these unique classes of compounds.
